Clinical trial · Observational
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study
NCT00096590CI-TRIAL-00002300completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thromboembolism | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| coagulation study | Other | — | UNRESOLVED |
| immunoenzyme technique | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| physiologic testing | Other | — | UNRESOLVED |
| study of high risk factors | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of hypercoagulability
Secondary outcomes (1)
- measure
- Comparison of the results of whole blood thrombin generation assay tests in patients who develop venous thromboembolism with those who do not
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Patients meeting the following criteria:
* Diagnosis of metastatic carcinoma
* Must be enrolled in 1 of the following surgical protocols:
* NCI-99-C-0123
* NCI-00-C-0069
* NCI-03-C-0085
* NCI-03-C-0212
* Healthy control participant\* meeting the following criteria:
* No anemia or thrombocytopenia
* No history of venous thromboembolism (deep vein thrombosis, pulmonary emboli)
* No history of coronary artery disease or stroke
* No chronic inflammatory disease
* No diabetes mellitus
* Have not smoked tobacco within the past 6 months NOTE: \* Selected on the basis of gender and age to match the patients as they are accrued
PATIENT CHARACTERISTICS:
* No symptomatic infections or other acute illness within the past 14 days
PRIOR CONCURRENT THERAPY:
* At least 3 days since prior drugs known to inhibit platelet function
* At least 7 days since prior acetylsalicylic acid
* No concurrent estrogen contraceptives or hormone replacement therapy
* No concurrent anticoagulantsReferences
Publications (1)
- RESULTHorne MK 3rd, Merryman PK, Cullinane AM, Nghiem K, Alexander HR. The impact of major surgery on blood coagulation factors and thrombin generation. Am J Hematol. 2007 Sep;82(9):815-20. doi: 10.1002/ajh.20963. PMID 17570509